Affiliation:
1. University of Haifa
2. Salk Institute for Biological Studies
3. Victor Babes National Institute of Pathology
4. University of California, San Diego
5. Tel Aviv University
6. Dalhousie University
Abstract
Abstract
Bipolar disorder (BD) is a neuropsychiatric mood disorder manifested by recurrent episodes of mania and depression. More than half of BD patients are non-responsive to lithium, the first-line treatment drug, complicating BD clinical management. Given its unknown etiology, it is pertinent to understand the genetic signatures that lead to variability in lithium treatment. We discovered a set of differentially expressed genes from the LCLs of 10 controls and 19 BD patients belonging mainly to the immunoglobulin gene family that can be used as potential biomarkers to diagnose and treat BD. Importantly, we trained a machine learning algorithm on our datasets that predicted the lithium response of BD subtypes with no errors, even when used on a different cohort of 24 BD patients acquired by a different laboratory. This proves the scalability of our methodology for predicting lithium response in BD and for a prompt and suitable decision on therapeutic interventions.
Publisher
Research Square Platform LLC
Reference84 articles.
1. A review of bipolar disorder in adults;Hilty DM;Psychiatry (Edgmont),2006
2. A review of bipolar disorder among adults;Hilty DM;Psychiatr Serv,1999
3. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder;Soreca I;J Psychiatr Res,2008
4. Bipolar disorder;Belmaker RH;N Engl J Med,2004
5. (!!! INVALID CITATION !!! 1,4,5).